The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti‐FVIII antibody

Documenti analoghi

• Minimal interference of concizumab with standard clinical coagulation laboratory assays – An in vitro study
  di: Cecilia Augustsson, et al.
  Pubblicazione: (2024)
• Challenges in the diagnosis and management of patients with rare coagulation disorders in Lebanon and consequences of a social and economic crisis
  di: Roula Farah, et al.
  Pubblicazione: (2024)
• Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State
  di: Yuki Kawasaki, et al.
  Pubblicazione: (2025)
• FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives
  di: Tadashi Matsushita, et al.
  Pubblicazione: (2026)
• In vitro combined haemostatic efficacy of emicizumab and extended half‐life factor VIII compounds
  di: Laurie Josset, et al.
  Pubblicazione: (2025)